Kraematon Investment Advisors Inc. Has $2.26 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Kraematon Investment Advisors Inc. trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,462 shares of the company’s stock after selling 110 shares during the period. IDEXX Laboratories makes up approximately 2.2% of Kraematon Investment Advisors Inc.’s holdings, making the stock its 15th biggest holding. Kraematon Investment Advisors Inc.’s holdings in IDEXX Laboratories were worth $2,258,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC increased its position in shares of IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after buying an additional 60 shares in the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in IDEXX Laboratories during the 2nd quarter worth $36,000. Finally, Ashton Thomas Securities LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter worth $37,000. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.18% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of research analyst reports. Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Piper Sandler restated a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. JPMorgan Chase & Co. cut their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Finally, Barclays lowered their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $539.63.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $428.62 on Friday. The stock has a market capitalization of $35.10 billion, a price-to-earnings ratio of 41.33, a PEG ratio of 3.52 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The firm has a fifty day simple moving average of $423.97 and a 200 day simple moving average of $458.74. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the business posted $2.53 EPS. Research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.